Axsome Therapeutics, Inc. (LON:0HKF)
London · Delayed Price · Currency is GBP · Price in USD 126.72
-1.63 (-1.27%)
At close: Oct 16, 2025
Axsome Therapeutics Employees
Axsome Therapeutics had 683 employees as of December 31, 2024. The number of employees increased by 138 or 25.32% compared to the previous year.
Employees
683
Change (1Y)
138
Growth (1Y)
25.32%
Revenue / Employee
427.10K GBP
Profits / Employee
-213.02K GBP
Market Cap
4.77B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 683 | 138 | 25.32% |
| Dec 31, 2023 | 545 | 162 | 42.30% |
| Dec 31, 2022 | 383 | 275 | 254.63% |
| Dec 31, 2021 | 108 | 48 | 80.00% |
| Dec 31, 2020 | 60 | 15 | 33.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Spire Healthcare Group | 15,703 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,500 |
Axsome Therapeutics News
- 8 days ago - Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating - Seeking Alpha
- 9 days ago - Axsome Therapeutics (AXSM) Supports Mental Illness Awareness Week - GuruFocus
- 9 days ago - Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community - GlobeNewsWire
- 11 days ago - Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 - GlobeNewsWire
- 17 days ago - AXSM: New 'Buy' Rating from B. Riley Securities with $179 PT | AXSM Stock News - GuruFocus
- 4 weeks ago - Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript - Seeking Alpha
- 4 weeks ago - Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025 - GlobeNewsWire
- 5 weeks ago - Axsome Therapeutics Stock Sees RS Rating Rise To 82 - Investor's Business Daily